Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:category |
gptkb:public_company
medical diagnostics company |
| gptkbp:CEO |
Nicole Sandford
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
women's health diagnostics
|
| gptkbp:formerName |
gptkb:Vermillion,_Inc.
|
| gptkbp:foundedYear |
1993
|
| gptkbp:headquartersLocation |
gptkb:Austin,_Texas,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aspira Women's Health Inc.
|
| gptkbp:industry |
gptkb:biotechnology
healthcare |
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:product |
gptkb:OVA1
gptkb:OVERA OVA1plus |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
ovarian cancer risk assessment
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:AWH
|
| gptkbp:website |
https://aspirawh.com/
|
| gptkbp:bfsParent |
gptkb:Vermillion,_Inc.
|
| gptkbp:bfsLayer |
7
|